



## Emisphere Technologies Announces Third Quarter 2009 Conference Call

### Conference Call/Webcast to be Held Monday, November 9, 2009 at 10:00 AM EST

CEDAR KNOLLS, N.J., Nov 04, 2009 (BUSINESS WIRE) -- Emisphere Technologies, Inc. (OTCBB:EMIS) announced today that management will host a conference call to discuss the Company's financial and operational results for the third quarter ended September 30, 2009 on Monday, November 9, 2009 at 10:00 AM EST. A press release will be issued prior to market open.

The live webcast of the conference call can be accessed through the company's web site at: [www.emisphere.com](http://www.emisphere.com). The live conference call dial-in number is: 1-877-852-6579(United States and Canada) or 1-719-325-4772 (International). In addition, an archive of the webcast can be accessed through the same link; an audio replay of the call will be available beginning at 1:00 PM EST through midnight on September 23, 2009 by calling 1-888-203-1112(United States and Canada) or 1-719-457-0820 (International). The conference replay PIN is 3548334.

### **About Emisphere Technologies, Inc.**

Emisphere is a biopharmaceutical company that focuses on a unique and improved delivery of therapeutic molecules or nutritional supplements using its Eligen<sup>(R)</sup> Technology. These molecules and compounds could be currently available or in development. Such molecules are usually delivered by injection; in many cases, their benefits are limited due to poor bioavailability, slow on-set of action or variable absorption. The Eligen<sup>(R)</sup> Technology can be applied to the oral route of administration as well other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal. The company's website is: [www.emisphere.com](http://www.emisphere.com).

### *Safe Harbor Statement Regarding Forward-looking Statements*

*The statements in this release and oral statements made by representatives of Emisphere relating to matters that are not historical facts (including without limitation those regarding the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Emisphere's product candidates and the sufficiency of Emisphere's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval in the United States or abroad, the ability of Emisphere and/or its partners to develop, manufacture and commercialize products using Emisphere's drug delivery technology, Emisphere's ability to fund such efforts with or without partners, and other risks and uncertainties detailed in Emisphere's filings with the Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in Emisphere's Annual Report on Form 10-K (file no. [000-17758](#)) filed on March 16, 2009.*

SOURCE: Emisphere Technologies, Inc.

### **Media Relations:**

West Mill Communications  
James G. Modica, 908-872-4919  
[jimwmm@aol.com](mailto:jimwmm@aol.com)

or

Emisphere Technologies  
Daria Palestina, 973-532-8002  
[dpalestina@emisphere.com](mailto:dpalestina@emisphere.com)

or

### **Investor Relations:**

Rx Communications Group  
Paula Schwartz, 917-322-2216  
[pschwartz@rxir.com](mailto:pschwartz@rxir.com)